title: High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects.
abstract: Fatty acids accumulate in the muscle cells in some carnitine deficiency syndromes due to a variety of genetic defects in intermediary metabolism. L-Carnitine administration may relieve this excess by transporting acyl compounds out of the cell as acylcarnitine. Similar fatty acid accumulation occurs during myocardial ischaemia because of the decreased rate of beta-oxidation, and this has been put forward as a cause of ventricular arrhythmias. This study was carried out to investigate whether administration of high doses of i.v. L-carnitine in patients with acute myocardial infarction could increase urinary excretion of acylcarnitine and reduce early ventricular arrhythmias. Fifty-six patients suffering from acute myocardial infarction, admitted to the Coronary Unit between 3 and 12 h after the onset of symptoms, were included in the study. The design of the study was double blind, parallel and placebo controlled. Allocation of treatment to patients was done randomly after stratification (time from onset of pain and site of infarction). The first group (28 patients) received intravenous L-carnitine at a dose of 100 mg kg-1 b.w. every 12 h for 36 h while the second group (28 patients) received placebo intravenously. Immediately before starting treatment two blood samples were taken (at 5-min intervals) and a further 16 samples were taken at regular intervals over the following 48 h. Patients' urine was collected over the same period of time. Concentrations of free carnitine, short chain acylcarnitine esters and long chain acylcarnitine esters in serum and urine were measured.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cattedra di Cardiologia, University of Bari, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Rizzon
authors.forename: G
authors.initials: G
authors.lastname: Biasco
authors.forename: M
authors.initials: M
authors.lastname: Di Biase
authors.forename: F
authors.initials: F
authors.lastname: Boscia
authors.forename: U
authors.initials: U
authors.lastname: Rizzo
authors.forename: F
authors.initials: F
authors.lastname: Minafra
authors.forename: A
authors.initials: A
authors.lastname: Bortone
authors.forename: N
authors.initials: N
authors.lastname: Siliprandi
authors.forename: A
authors.initials: A
authors.lastname: Procopio
authors.forename: E
authors.initials: E
authors.lastname: Bagiella
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000097:blood / Q000652:urine; D002331:Carnitine / Q000008:administration & dosage* / Q000097:blood / Q000652:urine; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000889:Anti-Arrhythmia Agents; D002331:Carnitine